Be at Med-e-Tel 2009 to Meet a Highly Qualified eHealth Audience

1-3 April, 2009, Luxembourg
An extensive international program with participants from 50 countries in Europe and around the world will put your company and solutions in front of an audience that is looking to see and hear the latest developments in telemedicine and eHealth. Supported by the International Society for Telemedicine & eHealth, European Commission, World Health Organization, International Telecommunication Union, European Association of CyberTherapy & Rehabilitation, and a range of other associations, the Med-e-Tel event gathers European and global healthcare leaders and providers.

A regional seminar, specifically targeted at healthcare administrators and professionals, is the ideal opportunity to profile your company and services among local stakeholders and to develop your business in the Luxembourg and Belgian marketplace. The seminar is an integral part of the Med-e-Tel conference program and is endorsed by the Luxembourg Ministry of Health and the CRP-Santé (Public Institute for Research in Healthcare, Public Health and Biotechnology).

Products and services on display, include:

  • computer hard/software and peripherals
  • consulting services
  • diagnostic/monitoring systems and devices
  • electronic health cards
  • electronic medical records and personal health records
  • hospital information systems
  • imaging devices
  • internet/intranet services
  • mobile/wireless devices
  • satellite communication
  • secure data transmission
  • surgical systems
  • systems integration
  • telecommunication services and devices
  • telecare/telehealth/telemedicine equipment and assistive technologies
  • videoconferencing
  • vital signs monitoring

Benefits and marketing opportunities for sponsors and exhibitors include:

  • stand space on the Med-e-Tel expo and catering area
  • extensive coverage in the Med-e-Tel newsletters
  • acknowledgement on the Med-e-Tel website
  • opportunity to make presentations or hold a workshop in the Med-e-Tel conference program
  • access to business lounge to organize client or sales meetings and presentations during the event
  • access to all conference sessions (an incredible educational, learning and networking experience!) for your personnel and invitees
  • advertising in the Conference and Exhibition Guide
  • signage at the event and in the conference rooms
  • coverage in international trade press
  • conference bag inserts
  • coffee break, lunch or reception sponsorships
  • access to delegate list
  • unlimited networking opportunities during the entire three days of the event, including two special networking receptions

Profile your company or organization as a major player in ehealth and telemedicine and gain valuable access to health, industry and government decision makers. To discuss sponsorship, exhibiting and presentation opportunities, send an e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it.

For further information, please visit:
http://www.medetel.eu

About Med-e-Tel
Med-e-Tel focuses on ehealth and telemedicine applications and a wide range of other medical ICT applications and on the convergence of information and communication technology with medical applications, which lead to higher quality of care, cost reductions, workflow efficiency, and widespread availability of healthcare services.

The "Med" in Med-e-Tel stands for healthcare services (institutional and home based care, prevention and education) and for medical products and equipment (medical imaging equipment, monitoring devices, electronic health records, etc.).
The "e" stands for the electronic and IT industry and services (hard- & software, internet, e-mail, etc.).
The "Tel" stands for telecommunications (whether it is POTS, ISDN, wireless, satellite, videoconferencing, VoIP, or other).

For further information, please visit www.medetel.lu.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...